Deal Watch: AstraZeneca/Almirall And Pfizer/Baxter Vaccines Deal Change Math On Future Pfizer/AstraZeneca Bid
Executive Summary
Meda acquires family-owned Italian firm Rottapharm for $3.1 billion, expanding its European and emerging markets business. Boehringer Ingelheim and Zealand sign their second collaboration, this time around peptide candidates for cardio-metabolic disease.
You may also be interested in...
Bigger And Smaller? Pfizer Pursues AstraZeneca But Hasn’t Given Up On A Split
A Pfizer break up is still an option even if the company completes a mega-merger with AstraZeneca, CEO Ian Read said May 5. The company’s first quarter sales and earnings results highlighted how important completing a transaction could be for the company, with sales down 9% and earnings down 15%.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.